TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock News

FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch

The U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027.

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency

Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option.

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Takeda Pharmaceutical Breaks Below 200-Day Moving Average - Notable for TAK

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda Pharmaceutical Enters Oversold Territory (TAK)

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking

/PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO: Toshio Fujimoto, "Ciconia") today announced its establishment as a joint...

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Vatroslav Mateljic Appointed General Manager of Takeda Canada

/CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the...

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024

Takeda Pharmaceutical just reported results for the first quarter of 2024.

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

3 Biotech Stocks to Buy on the Dip: July 2024

Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.